Copyright Reports & Markets. All rights reserved.

Global Fam-Trastuzumab Deruxtecan Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Fam-Trastuzumab Deruxtecan Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 5.4 mg/kg
    • 1.3.3 6.4 mg/kg
  • 1.4 Market Analysis by Antibody Type
    • 1.4.1 Overview: Global Fam-Trastuzumab Deruxtecan Consumption Value by Antibody Type: 2021 Versus 2025 Versus 2032
    • 1.4.2 Monoclonal Antibody
    • 1.4.3 Polyclonal Antibody
  • 1.5 Market Analysis by Dosage Form
    • 1.5.1 Overview: Global Fam-Trastuzumab Deruxtecan Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
    • 1.5.2 Lyophilized Powder For Injection
    • 1.5.3 Concentrate For Intravenous Infusion
  • 1.6 Market Analysis by Production Technology
    • 1.6.1 Overview: Global Fam-Trastuzumab Deruxtecan Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
    • 1.6.2 Innovator
    • 1.6.3 Generic
  • 1.7 Market Analysis by Application
    • 1.7.1 Overview: Global Fam-Trastuzumab Deruxtecan Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.7.2 HER2-Positive Breast Cancer
    • 1.7.3 HER2-Positive Gastric and Gastroesophageal Junction Cancer
    • 1.7.4 HER2-Mutant Non-Small Cell Lung Cancer
    • 1.7.5 Others
  • 1.8 Global Fam-Trastuzumab Deruxtecan Market Size & Forecast
    • 1.8.1 Global Fam-Trastuzumab Deruxtecan Consumption Value (2021 & 2025 & 2032)
    • 1.8.2 Global Fam-Trastuzumab Deruxtecan Sales Quantity (2021-2032)
    • 1.8.3 Global Fam-Trastuzumab Deruxtecan Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Daiichi Sankyo
    • 2.1.1 Daiichi Sankyo Details
    • 2.1.2 Daiichi Sankyo Major Business
    • 2.1.3 Daiichi Sankyo Fam-Trastuzumab Deruxtecan Product and Services
    • 2.1.4 Daiichi Sankyo Fam-Trastuzumab Deruxtecan Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Daiichi Sankyo Recent Developments/Updates
  • 2.2 AstraZeneca
    • 2.2.1 AstraZeneca Details
    • 2.2.2 AstraZeneca Major Business
    • 2.2.3 AstraZeneca Fam-Trastuzumab Deruxtecan Product and Services
    • 2.2.4 AstraZeneca Fam-Trastuzumab Deruxtecan Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 AstraZeneca Recent Developments/Updates

3 Competitive Environment: Fam-Trastuzumab Deruxtecan by Manufacturer

  • 3.1 Global Fam-Trastuzumab Deruxtecan Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Fam-Trastuzumab Deruxtecan Revenue by Manufacturer (2021-2026)
  • 3.3 Global Fam-Trastuzumab Deruxtecan Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Fam-Trastuzumab Deruxtecan by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Fam-Trastuzumab Deruxtecan Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Fam-Trastuzumab Deruxtecan Manufacturer Market Share in 2025
  • 3.5 Fam-Trastuzumab Deruxtecan Market: Overall Company Footprint Analysis
    • 3.5.1 Fam-Trastuzumab Deruxtecan Market: Region Footprint
    • 3.5.2 Fam-Trastuzumab Deruxtecan Market: Company Product Type Footprint
    • 3.5.3 Fam-Trastuzumab Deruxtecan Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Fam-Trastuzumab Deruxtecan Market Size by Region
    • 4.1.1 Global Fam-Trastuzumab Deruxtecan Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Fam-Trastuzumab Deruxtecan Consumption Value by Region (2021-2032)
    • 4.1.3 Global Fam-Trastuzumab Deruxtecan Average Price by Region (2021-2032)
  • 4.2 North America Fam-Trastuzumab Deruxtecan Consumption Value (2021-2032)
  • 4.3 Europe Fam-Trastuzumab Deruxtecan Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Fam-Trastuzumab Deruxtecan Consumption Value (2021-2032)
  • 4.5 South America Fam-Trastuzumab Deruxtecan Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Fam-Trastuzumab Deruxtecan Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Fam-Trastuzumab Deruxtecan Sales Quantity by Type (2021-2032)
  • 5.2 Global Fam-Trastuzumab Deruxtecan Consumption Value by Type (2021-2032)
  • 5.3 Global Fam-Trastuzumab Deruxtecan Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Fam-Trastuzumab Deruxtecan Sales Quantity by Application (2021-2032)
  • 6.2 Global Fam-Trastuzumab Deruxtecan Consumption Value by Application (2021-2032)
  • 6.3 Global Fam-Trastuzumab Deruxtecan Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Fam-Trastuzumab Deruxtecan Sales Quantity by Type (2021-2032)
  • 7.2 North America Fam-Trastuzumab Deruxtecan Sales Quantity by Application (2021-2032)
  • 7.3 North America Fam-Trastuzumab Deruxtecan Market Size by Country
    • 7.3.1 North America Fam-Trastuzumab Deruxtecan Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Fam-Trastuzumab Deruxtecan Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Fam-Trastuzumab Deruxtecan Sales Quantity by Type (2021-2032)
  • 8.2 Europe Fam-Trastuzumab Deruxtecan Sales Quantity by Application (2021-2032)
  • 8.3 Europe Fam-Trastuzumab Deruxtecan Market Size by Country
    • 8.3.1 Europe Fam-Trastuzumab Deruxtecan Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Fam-Trastuzumab Deruxtecan Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Fam-Trastuzumab Deruxtecan Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Fam-Trastuzumab Deruxtecan Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Fam-Trastuzumab Deruxtecan Market Size by Region
    • 9.3.1 Asia-Pacific Fam-Trastuzumab Deruxtecan Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Fam-Trastuzumab Deruxtecan Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Fam-Trastuzumab Deruxtecan Sales Quantity by Type (2021-2032)
  • 10.2 South America Fam-Trastuzumab Deruxtecan Sales Quantity by Application (2021-2032)
  • 10.3 South America Fam-Trastuzumab Deruxtecan Market Size by Country
    • 10.3.1 South America Fam-Trastuzumab Deruxtecan Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Fam-Trastuzumab Deruxtecan Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Fam-Trastuzumab Deruxtecan Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Fam-Trastuzumab Deruxtecan Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Fam-Trastuzumab Deruxtecan Market Size by Country
    • 11.3.1 Middle East & Africa Fam-Trastuzumab Deruxtecan Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Fam-Trastuzumab Deruxtecan Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Fam-Trastuzumab Deruxtecan Market Drivers
  • 12.2 Fam-Trastuzumab Deruxtecan Market Restraints
  • 12.3 Fam-Trastuzumab Deruxtecan Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Fam-Trastuzumab Deruxtecan and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Fam-Trastuzumab Deruxtecan
  • 13.3 Fam-Trastuzumab Deruxtecan Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Fam-Trastuzumab Deruxtecan Typical Distributors
  • 14.3 Fam-Trastuzumab Deruxtecan Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Fam-Trastuzumab Deruxtecan market size was valued at US$ 4500 million in 2025 and is forecast to a readjusted size of US$ 17495 million by 2032 with a CAGR of 17.4% during review period.
    Fam-Trastuzumab Deruxtecan (T-DXd) is a new-generation human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC). It is covalently composed of a humanized anti-HER2 monoclonal antibody, a cleavable tetrapeptide linker, and DXd, a topoisomerase I inhibitor, with a high drug-to-antibody ratio of 8:1. The drug specifically binds to the HER2 receptor on the surface of tumor cells, and releases highly potent cytotoxic payloads after internalization into cells. It exerts a strong anti-tumor effect by inhibiting DNA replication and inducing apoptosis, and also exhibits a bystander killing effect, showing significant activity against HER2-low expressing tumors. Clinically, it is mainly used for the treatment of solid tumors such as HER2-positive breast cancer, gastric cancer, esophageal cancer and non-small cell lung cancer. With excellent efficacy and favorable safety, it has become a landmark anti-tumor drug with the broadest indications and outstanding clinical value among global ADCs.In 2025, global Fam-Trastuzumab Deruxtecan production reached approximately 4,373,000 vials.
    As a benchmark product in the global ADC drug sector, fam-trastuzumab deruxtecan has become a core therapeutic option for HER2-positive solid tumors due to its superior clinical efficacy, broad indication layout, and leading technological advantages. Its market position is supported by multiple barriers: in terms of efficacy, the drug is not only the gold standard for second-line treatment of HER2-positive breast cancer but also pioneeringly covers HER2-low expressing populations, significantly expanding its applicable scope. In indication expansion, it has been approved for multiple cancers including breast cancer, gastric cancer, and non-small cell lung cancer, with ongoing research in early-stage treatment and combination therapy. Commercially, it has achieved rapid global penetration, and its accessibility in China has greatly improved after inclusion in medical insurance, making it a core growth engine.
    In the current competitive landscape, fam-trastuzumab deruxtecan maintains an absolutely dominant position. Although facing competition from domestic agents such as disitamab vedotin and ado-trastuzumab emtansine in China, it retains a stable market share owing to its advantages in efficacy and breadth of indications. In the future, with the approval of new indications, deeper deployment in early treatment, and wider medical insurance coverage worldwide, its market potential will be further unlocked. Meanwhile, the rapid rise of domestic ADC drugs will intensify competition, forcing it to consolidate its leading position through technological upgrading, price optimization, and differentiated strategies.
    This report is a detailed and comprehensive analysis for global Fam-Trastuzumab Deruxtecan market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Fam-Trastuzumab Deruxtecan market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Fam-Trastuzumab Deruxtecan market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Fam-Trastuzumab Deruxtecan market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Fam-Trastuzumab Deruxtecan market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Fam-Trastuzumab Deruxtecan
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Fam-Trastuzumab Deruxtecan market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Daiichi Sankyo, AstraZeneca, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Fam-Trastuzumab Deruxtecan market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    5.4 mg/kg
    6.4 mg/kg
    Market segment by Antibody Type
    Monoclonal Antibody
    Polyclonal Antibody
    Market segment by Dosage Form
    Lyophilized Powder For Injection
    Concentrate For Intravenous Infusion
    Market segment by Production Technology
    Innovator
    Generic
    Market segment by Application
    HER2-Positive Breast Cancer
    HER2-Positive Gastric and Gastroesophageal Junction Cancer
    HER2-Mutant Non-Small Cell Lung Cancer
    Others
    Major players covered
    Daiichi Sankyo
    AstraZeneca
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Fam-Trastuzumab Deruxtecan product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Fam-Trastuzumab Deruxtecan, with price, sales quantity, revenue, and global market share of Fam-Trastuzumab Deruxtecan from 2021 to 2026.
    Chapter 3, the Fam-Trastuzumab Deruxtecan competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Fam-Trastuzumab Deruxtecan breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Fam-Trastuzumab Deruxtecan market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Fam-Trastuzumab Deruxtecan.
    Chapter 14 and 15, to describe Fam-Trastuzumab Deruxtecan sales channel, distributors, customers, research findings and conclusion.

    Buy now